Amgen's MariTide: Promising Weight Loss with Milder Side Effects
Amgen's experimental obesity drug MariTide showed promising weight loss results with fewer side effects, according to a mid-stage trial. The company is launching a 72-week Phase 3 trial, with plans for further studies in cardiovascular and respiratory conditions. The drug activates appetite-reducing hormones and improves cardiometabolic measures.
In a recent medical meeting, Amgen's long-acting obesity drug MariTide demonstrated equivalent weight loss to high doses with fewer side effects. This emerged from a mid-stage trial's complete results.
A 72-week Phase 3 trial is now set to analyze three dosages, initiating at lower levels, according to Amgen's Jay Bradner.
Previously, the Phase 2 trial's top-line outcomes indicated significant weight loss among users. The drug, targeting GLP-1 and GIP hormones, also enhances cardiometabolic health with no new safety issues reported.
(With inputs from agencies.)
- READ MORE ON:
- Amgen
- MariTide
- obesity
- weight loss
- clinical trial
- Phase 3
- GLP-1
- GIP
- hormones
- cardiometabolic
Advertisement
Google News